KCNN1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3250242	1.00	2/20
Hydrochloric Acid (SCHEMBL3254146)	1.00	2/20
SCHEMBL5155715	1.00	2/20
SCHEMBL5157963	1.00	2/20
Hydrochloric Acid (SCHEMBL3248635)	0.94	2/20
SCHEMBL3253219	0.94	2/20
Hydrochloric Acid (SCHEMBL3250094)	0.92	2/20
Hydrochloric Acid (SCHEMBL5136925)	0.92	2/20
SCHEMBL3251892	0.91	2/20
SCHEMBL5173768	0.80	2/20
SCHEMBL6368980	0.75	2/20
SCHEMBL4397255	0.74	2/20
SCHEMBL6368825	0.74	2/20
SCHEMBL5155606	0.72	2/20
SCHEMBL6368664	0.72	2/20
SCHEMBL6372841	0.72	2/20
SCHEMBL6368865	0.71	2/20
SCHEMBL6369179	0.71	2/20
SCHEMBL1890717	0.70	2/20
SCHEMBL5456487	0.70	2/20

Clinical trials — most relevant to KCNN1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation	PHASE3	COMPLETED
Diuretics, Hypertension, and Arrhythmias Clinical Trial	PHASE3	COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
A Clinical Study to Evaluate CAD-1883 in Essential Tremor	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies	nan	UNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)	nan	COMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Impact of Persistent Conductances on Motor Unit Firing in SCI	nan	UNKNOWN
Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNN1 binder may also engage these)

Protein	Name	Similarity
P70606	—	0.997	P70606 →
Q9EQR3	—	0.992	Q9EQR3 →
P70604	—	0.980	P70604 →
Q52PG9	—	0.978	Q52PG9 →
Q9Y613	—	0.978	Q9Y613 →
KCNN2	Small conductance calcium-activated potassium channel protein 2	0.977	landscape →
Q9ESJ4	—	0.977	Q9ESJ4 →
KCNA6	Potassium voltage-gated channel subfamily A member 6	0.977	landscape →
P25122	—	0.977	P25122 →
P17659	—	0.976	P17659 →
P50638	—	0.976	P50638 →
Q14B80	—	0.976	Q14B80 →
O89109	—	0.976	O89109 →
Q96PR1	—	0.976	Q96PR1 →
KCNC1	Voltage-gated potassium channel KCNC1	0.976	landscape →
Q8IUH8	—	0.976	Q8IUH8 →
P19024	—	0.975	P19024 →
KCNN3	Small conductance calcium-activated potassium channel protein 3	0.975	landscape →
Q64347	—	0.975	Q64347 →
Q03719	—	0.975	Q03719 →
Q5RD44	—	0.975	Q5RD44 →
Q9Z0S8	—	0.975	Q9Z0S8 →
P70218	—	0.975	P70218 →
P04920	—	0.975	P04920 →
Q61762	—	0.974	Q61762 →
Q5T197	—	0.974	Q5T197 →
Q9NSA2	—	0.974	Q9NSA2 →
P58392	—	0.974	P58392 →
P15388	—	0.974	P15388 →
KCNA5	Potassium voltage-gated channel subfamily A member 5	0.974	landscape →